Back Login for AI Analysis

    AARD (STOCKS)

    Aardvark Therapeutics, Inc. Common Stock

    $3.820000
    +0.100000 (+2.69%)
    Prev close: $3.720000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Tien Li Lee
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $82.90M
    Employees
    31
    P/E (TTM)
    -1.19
    P/B (TTM)
    0.96
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Mar 2026)
    Revenues -$1.18M
    Nonoperating Income/Loss $4.85M
    Operating Expenses $74.72M
    Research and Development $57.75M
    Other Operating Expenses $16.97M
    Operating Income/Loss -$74.72M
    Income/Loss From Continuing Operations After Tax -$69.87M
    Income/Loss From Continuing Operations Before Tax -$80.35M
    Interest And Dividend Income, Operating $4.85M
    Net Income/Loss -$69.87M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$69.87M
    Net Income/Loss Available To Common Stockholders, Basic -$69.87M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$3.21
    Diluted Earnings Per Share -$3.21
    Basic Average Shares 28,245,903
    Diluted Average Shares 28,245,903
    Assets $98.59M
    Current Assets $93.58M
    Cash $91.20M
    Other Current Assets $2.38M
    Noncurrent Assets $5.01M
    Liabilities $11.60M
    Current Liabilities $11.60M
    Accounts Payable $4.49M
    Wages $1.52M
    Other Current Liabilities $5.59M
    Noncurrent Liabilities $0.00
    Equity $86.99M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $86.99M
    Liabilities And Equity $98.59M
    Net Cash Flow From Operating Activities -$61.65M
    Net Cash Flow From Operating Activities, Continuing -$61.65M
    Net Cash Flow From Investing Activities $97.21M
    Net Cash Flow From Investing Activities, Continuing $97.21M
    Net Cash Flow From Financing Activities $378.00K
    Net Cash Flow From Financing Activities, Continuing $378.00K
    Net Cash Flow $35.93M
    Net Cash Flow, Continuing $35.93M
    Comprehensive Income/Loss -$69.90M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$69.90M
    Other Comprehensive Income/Loss -$69.90M